HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Expands 'OTC' Business, China Presence With Mead Johnson

This article was originally published in The Pink Sheet

Executive Summary

Marketing Enfamil and other Mead Johnson formula and nutritional brands, says RB CEO Rakesh Kapoor, is "very much in the core of what consumer health stands for," and also immediately doubles the size of the firm's consumer business.

You may also be interested in...



RB Eyes MJN, Spiked Supplements, GMP Warning: Health & Wellness Industry News Roundup

RB eyes acquiring MJN; weight loss, ED drugs found in supplements; Unique EnCapsulation has GMP, water, expiration date problems; and SSCI Benchmark panel nominees sought.

Industry Roundup: SEC Fines MJN, Criminal Charge For Herbals Seller, Decree Closes Aspen Supplement Marketer

FCPA violations cost Mead Johnson $12M; decree closes Aspen supplement marketer; equity funding for SmartyPants; homeopathic online retailer warned; ForeverGreen launches strong; and more news in brief.

China Tightens Infant Formula Industry Oversight, Levels Playing Field

China steps up oversight of pricing and compliance in the infant formula industry, imposing requirements similar to those for drug manufacturers. To tighten supervision, CFDA publishes new rules on manufacturing and marketing that raise standards and prohibit promotion of formula to medical institutions.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel